Evgen Pharma plc
EVG.L
London Stock Exchange0.82
GBp
+0.02
- -
Evgen Pharma plc
EVG.L
(London Stock Exchange)
Recent
price
0.82
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Evgen Pharma plc operates as a clinical-stage biotechnology firm, dedicated to advancing novel therapies derived primarily from sulforaphane for a range of serious conditions. The company’s innovative approach centers on its proprietary Sulforadex technology, which successfully synthesizes and stabilizes sulforaphane, a naturally occurring compound, into a pharmaceutical-grade ingredient. The flagship compound, SFX-01, a synthetic sulforaphane composition, has shown promising efficacy in completed Phase II trials for metastatic breast cancer. It is also progressing through clinical investigation, including an upcoming investigator-sponsored study in glioblastoma, for which it has received Orphan Drug Designation from the FDA. Evgen has recently refined its delivery with a new enteric-coated tablet formulation, successfully evaluated in a Phase 1b healthy volunteer study. Beyond oncology, SFX-01 is being explored for neurodevelopmental disorders such as Autism Spectrum Disorder through a partnership with Stalicla SA, following a completed Phase 1b pharmacokinetic/pharmacodynamic study. Preclinical efforts are additionally underway for various other indications, including colorectal cancer and rhabdomyosarcoma. Evgen Pharma's strategy involves developing its drug candidates to proof-of-concept stages and then pursuing licensing agreements with larger pharmaceutical entities, aiming for milestone payments and royalties. The company expanded its pipeline in March 2024 through the acquisition of Chronos Therapeutics Limited, adding preclinical assets for addictive behaviors, fatigue, and narcolepsy. Established in 2014, Evgen Pharma plc is headquartered in Alderley Park, United Kingdom.